|
1.Kleihues, P., P.C. Burger, and B.W. Scheithauer, The new WHO classification of brain tumours. Brain Pathol, 1993. 3(3): p. 255-68. 2.Rao, J.S., Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer, 2003. 3(7): p. 489-501. 3.Maher, E.A., et al., Malignant glioma: genetics and biology of a grave matter. Genes Dev, 2001. 15(11): p. 1311-33. 4.Louis, D.N., Molecular pathology of malignant gliomas. Annu Rev Pathol, 2006. 1: p. 97-117. 5.Omuro, A. and L.M. DeAngelis, Glioblastoma and other malignant gliomas: a clinical review. Jama, 2013. 310(17): p. 1842-50. 6.Stupp, R., et al., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med, 2005. 352(10): p. 987-96. 7.Heimberger, A.B. and J.H. Sampson, Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma? Neuro Oncol, 2011. 13(1): p. 3-13. 8.Gabrilovich, D., et al., Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood, 1998. 92(11): p. 4150-66. 9.Platten, M., W. Wick, and M. Weller, Malignant glioma biology: role for TGF-beta in growth, motility, angiogenesis, and immune escape. Microsc Res Tech, 2001. 52(4): p. 401-10. 10.Ge, L., et al., Immunotherapy of brain cancers: the past, the present, and future directions. Clin Dev Immunol, 2010. 2010: p. 296453. 11.Gabrilovich, D.I., et al., Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med, 1996. 2(10): p. 1096-103. 12.Munn, D.H. and A.L. Mellor, IDO and tolerance to tumors. Trends Mol Med, 2004. 10(1): p. 15-8. 13.Keller, A.D. and T. Maniatis, Identification and characterization of a novel repressor of beta-interferon gene expression. Genes Dev, 1991. 5(5): p. 868-79. 14.Turner, C.A., Jr., D.H. Mack, and M.M. Davis, Blimp-1, a novel zinc finger-containing protein that can drive the maturation of B lymphocytes into immunoglobulin-secreting cells. Cell, 1994. 77(2): p. 297-306. 15.Vincent, S.D., et al., The zinc finger transcriptional repressor Blimp1/Prdm1 is dispensable for early axis formation but is required for specification of primordial germ cells in the mouse. Development, 2005. 132(6): p. 1315-25. 16.Turner, C.A., Jr., D.H. Mack, and M.M. Davis, Pillars article: Blimp-1, a novel zinc finger-containing protein that can drive the maturation of B lymphocytes into immunoglobulin-secreting cells. 1994. J Immunol, 2010. 185(1): p. 5-14. 17.Fink, P.J., T cells join the Blimp-1 brigade. Nat Immunol, 2006. 7(5): p. 445-6. 18.Kallies, A. and S.L. Nutt, Terminal differentiation of lymphocytes depends on Blimp-1. Curr Opin Immunol, 2007. 19(2): p. 156-62. 19.Martins, G. and K. Calame, Regulation and functions of Blimp-1 in T and B lymphocytes. Annu Rev Immunol, 2008. 26: p. 133-69. 20.Martins, G.A., et al., Blimp-1 directly represses Il2 and the Il2 activator Fos, attenuating T cell proliferation and survival. J Exp Med, 2008. 205(9): p. 1959-65. 21.Cimmino, L., et al., Blimp-1 attenuates Th1 differentiation by repression of ifng, tbx21, and bcl6 gene expression. J Immunol, 2008. 181(4): p. 2338-47. 22.Cretney, E., et al., The transcription factors Blimp-1 and IRF4 jointly control the differentiation and function of effector regulatory T cells. Nat Immunol, 2011. 12(4): p. 304-11. 23.Litman, G.W., J.P. Cannon, and L.J. Dishaw, Reconstructing immune phylogeny: new perspectives. Nat Rev Immunol, 2005. 5(11): p. 866-79. 24.Pancer, Z. and M.D. Cooper, The evolution of adaptive immunity. Annu Rev Immunol, 2006. 24: p. 497-518. 25.Schaefer, L.K., D.G. Menter, and T.S. Schaefer, Activation of stat3 and stat1 DNA binding and transcriptional activity in human brain tumour cell lines by gp130 cytokines. Cell Signal, 2000. 12(3): p. 143-51. 26.Humphries, W., et al., The role of tregs in glioma-mediated immunosuppression: potential target for intervention. Neurosurg Clin N Am, 2010. 21(1): p. 125-37. 27.Izumoto, S., et al., Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. J Neurosurg, 2008. 108(5): p. 963-71.
|